ReviewJournal of spine surgery (Hong Kong)2019
Stem cell therapy in discogenic back pain.
Review in Journal of spine surgery (Hong Kong), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- General Innovations in Pain Management.Journal of clinical medicine · 2025Review
- Clinical Efficacy and Risks of Intradiscal Orthobiological Injections: A Narrative Review.Current pain and headache reports · 2025Review
- Regenerative strategies for intervertebral disc degeneration.Journal of orthopaedic translation · 2025Review
- Targeted CRISPR regulation of ZNF865 enhances stem cell cartilage deposition, tissue maturation rates, and mechanical properties in engineered intervertebral discs.Acta biomaterialia · 2025Article
- Exosomes derived from human urine-derived stem cells ameliorate IL-1β-induced intervertebral disk degeneration.BMC musculoskeletal disorders · 2024Article
- Enhanced Intervertebral Disc Repair via Genetically Engineered Mesenchymal Stem Cells with Tetracycline Regulatory System.International journal of molecular sciences · 2023Article
- Research trends and hotspots of mesenchymal stromal cells in intervertebral disc degeneration: a scientometric analysis.EFORT open reviews · 2023Review
- An esterase-responsive ibuprofen nano-micelle pre-modified embryo derived nucleus pulposus progenitor cells promote the regeneration of intervertebral disc degeneration.Bioactive materials · 2023Article
- Elucidating the Focal Immunomodulatory Clues Influencing Mesenchymal Stem Cells in the Milieu of Intervertebral Disc Degeneration.Current stem cell research & therapy · 2023Article
- Review: Discogenic Back Pain: Update on Treatment.Orthopedic reviews · 2023Article
- Regenerative Medicine: Pharmacological Considerations and Clinical Role in Pain Management.Current pain and headache reports · 2022Review
- Article
- Mesenchymal Stem Cell-Derived Exosomes and Intervertebral Disc Regeneration: Review.International journal of molecular sciences · 2022Review
- Review
- Mesenchymal Stem Cell-Derived Exosomes as a Novel Strategy for the Treatment of Intervertebral Disc Degeneration.Frontiers in cell and developmental biology · 2021Review
- Notochordal Cell-Based Treatment Strategies and Their Potential in Intervertebral Disc Regeneration.Frontiers in cell and developmental biology · 2021Review
- Shaping the Microglia in Retinal Degenerative Diseases Using Stem Cell Therapy: Practice and Prospects.Frontiers in cell and developmental biology · 2021Review
- Stem Cell Therapy and Exercise for Treatment of Intervertebral Disc Degeneration.Stem cells international · 2021Review
- Autologous BMAC Therapy Improves Spinal Degenerative Joint Disease in Lower Back Pain Patients.Frontiers in medicine · 2021Article
- Exosomes derived from stem cells as an emerging therapeutic strategy for intervertebral disc degeneration.World journal of stem cells · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic low back pain has both substantial social and economic impacts on patients and healthcare budgets. Adding to the magnitude of the problem is the difficulty in identifying the exact causes of disc degeneration with modern day diagnostic and imaging techniques. With that said, current non-operative and surgical treatment modalities for discogenic low back pain fails to meet the expectations in many patients and hence the challenge. The objective for newly emerging stem cell regenerative therapy is to treat degenerative disc disease (DDD) by restoring the disc's cellularity and modulating the inflammatory response. Appropriate patient selection is crucial for the success of stem cell therapy. Regenerative modalities for discogenic pain currently focus on the use of either primary cells harvested from the intervertebral discs or stem cells from other sources whether autogenic or allogenic. The microenvironment in which stem cells are being cultured has been recognized to play a crucial role in directing or maintaining the production of the desired phenotypes and may enhance their regenerative potential. This has led to a more specific focus on innovating more effective culturing techniques, delivery vehicles and scaffolds for stem cell application. Although stem cell therapy might offer an attractive alternative treatment option, more clinical studies are still needed to establish on the safety and feasibility of such therapy. In this literature review, we aim to present the most recent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.